Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Higher cardiovascular risk scores and liver fibrosis risk estimated by biomarkers in patients with metabolic-dysfunction-associated fatty liver disease
Giovanni Alejandro Salgado Alvarez, Samanta Mayanin Pinto Galvez, Uriel Garcia Mora, Ana Delfina Cano Contreras, Cristina Durán Rosas, Bryan Adrián Priego-Parra, Arturo Triana Romero, Mercedes Amieva Balmori, Federico Roesch Dietlen, Sophia Eugenia Martinez Vazquez, Ines Osvely Mendez Guerrero, Luis Alberto Chi-Cervera, Raúl Bernal Reyes, Leonardo Alberto Martinez Roriguez, Maria Eugenia Icaza Chavez, Jose Maria Remes Troche
Giovanni Alejandro Salgado Alvarez, Samanta Mayanin Pinto Galvez, Uriel Garcia Mora, Ana Delfina Cano Contreras, Cristina Durán Rosas, Bryan Adrián Priego-Parra, Arturo Triana Romero, Mercedes Amieva Balmori, Federico Roesch Dietlen, Jose Maria Remes Troche, Instituto de Investigaciones Médico-biologicas, Universidad Veracruzana, Veracruz 91700, Veracruz, Mexico
Sophia Eugenia Martinez Vazquez, Ines Osvely Mendez Guerrero, Department of Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México 14080, México, Mexico
Luis Alberto Chi-Cervera, Clínica de Especialidades Gastrointestinales y Hepáticas, Hospital Star Medica, Merida 97133, Yucatan, Mexico
Raúl Bernal Reyes, Department of Gastroenterologia, Sociedad Española de Beneficencia, Pachuca 42000, Hidalgo, Mexico
Leonardo Alberto Martinez Roriguez, Department of Gastroenterologia, Clínica de Rehabilitación Metabólica Digestiva y Hepática, Mexico 14080, Mexico, Mexico
Maria Eugenia Icaza Chavez, Department of Gastroenterologia, Hospital Star Médica de Mérida, Merida 97133, Yucatan, Mexico
Author contributions: Salgado Alvarez GA, Pinto Galvez SM, Garcia Mora U and Cano Contreras AD contributed to the first writing of the manuscript, methodology, analysis of results; Durán Rosas C, Priego-Parra BA and Triana Romero A contributed to review and editing; Amieva Balmori M, Roesch Dietlen F, Martinez Vazquez SE and Mendez Guerrero IO contributed to the conception and development of research; Chi-Cervera LA, Bernal Reyes R, Martinez Roriguez LA, Icaza Chavez ME and Remes Troche JM contributed to the conception and development of research, project management, review and editing.
Supported by Asociación Mexicana de Gastroenterología, No. 2020-001.
Institutional review board statement: The study was reviewed and approved by the Instituto de Investigaciones Medico-biologicas de la Universidad Veracruzana Institutional Review Board CE-IIMB-2021-01.
Informed consent statement: Patients signed and provided the informed consent to this study.
Conflict-of-interest statement: All authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement, and the manuscript was prepared and revised according to the STROBE Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
https://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Ana Delfina Cano Contreras, MD, Attending Doctor, Instituto de Investigaciones Médico-biologicas, Universidad Veracruzana, C. Agustín de Iturbide, Veracruz 91700, Veracruz, Mexico.
anacano1403@gmail.com
Received: February 17, 2022
Peer-review started: February 17, 2022
First decision: April 5, 2022
Revised: April 15, 2022
Accepted: August 1, 2022
Article in press: August 1, 2022
Published online: August 27, 2022
Processing time: 189 Days and 15.7 Hours
ARTICLE HIGHLIGHTS
Research background
The investigation was carried out in an open population without a diagnosis of metabolic-dysfunction-associated fatty liver disease (MAFLD).
Research motivation
To identify patients with MAFLD and establish their cardiovascular risk (CVR).
Research objectives
The objective is to evaluate the relationship between fibrosis and steatosis measured by transition elastography in patients with MAFLD and CVR scores in Mexican patients.
Research methods
Identification of patients with MAFLD in the open population. Subsequently, determination of the risk of fibrosis by noninvasive methods. Finally, CVR was determined by the Framingham risk scale and was related to the presence of fibrosis and steatosis.
Research results
21.4% of the study population met MAFLD criteria. The severity of CVR was related to the presence of fibrosis, but not with the severity of steatosis.
Research conclusions
Patients with MAFLD and liver fibrosis have a higher CVR compared to patients without fibrosis, regardless of the severity of steatosis.
Research perspectives
Prospective research is required to determine the best CVR score in patients with MAFLD.
